Literature DB >> 6327295

Three different activated ras genes in mouse tumours; evidence for oncogene activation during progression of a mouse lymphoma.

K H Vousden, C J Marshall.   

Abstract

Five unrelated mouse tumours have been shown to carry activated transforming genes using the NIH/3T3 transfection assay. Three of these tumours, a T-cell lymphoma, a fibrosarcoma and a macrophage tumour, were found to carry an activated c-Ki-ras gene. A c-Ha-ras gene was shown to be activated in a myeloid leukaemia and a recently identified member of the 'ras' gene family, N-ras, was found to be activated in a lung carcinoma. The T-cell lymphoma, L5178Y-ES, is a more aggressively growing metastatic variant which arose spontaneously from the parental tumour, L5178Y-E. Although DNA from both parental and variant tumours was shown to transfer a genetic marker to recipient cells equally well, only the metastatic variant carried an activated c-Ki-ras gene detectable by transfection. The altered growth behaviour of the L5178Y-ES cells may therefore be the result of the spontaneous activation of the c-Ki-ras gene after the lymphoma cells had already become tumorigenic.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327295      PMCID: PMC557447          DOI: 10.1002/j.1460-2075.1984.tb01905.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  35 in total

1.  Characterization of mouse cellular deoxyribonucleic acid homologous to Abelson murine leukemia virus-specific sequences.

Authors:  B Dale; B Ozanne
Journal:  Mol Cell Biol       Date:  1981-08       Impact factor: 4.272

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin.

Authors:  C Shih; B Z Shilo; M P Goldfarb; A Dannenberg; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

4.  The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes.

Authors:  R W Ellis; D Defeo; T Y Shih; M A Gonda; H A Young; N Tsuchida; D R Lowy; E M Scolnick
Journal:  Nature       Date:  1981-08-06       Impact factor: 49.962

5.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel; G Urlaub; L Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

6.  Effects on in vitro tumor growth of murine macrophages isolated from sarcoma lines differing in immunogenicity and metastasizing capacity.

Authors:  A Mantovani
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

7.  Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus.

Authors:  R W Ellis; D DeFeo; J M Maryak; H A Young; T Y Shih; E H Chang; D R Lowy; E M Scolnick
Journal:  J Virol       Date:  1980-11       Impact factor: 5.103

8.  Effect of thymidine on the sensitivity of cultured mouse tumor cells to 1-beta-D-arabinofuranosylcytosine.

Authors:  A W Harris; E C Reynolds; L R Finch
Journal:  Cancer Res       Date:  1979-02       Impact factor: 12.701

Review 9.  The pathogenesis of cancer metastasis.

Authors:  G Poste; I J Fidler
Journal:  Nature       Date:  1980-01-10       Impact factor: 49.962

10.  Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumour.

Authors:  I Parr
Journal:  Br J Cancer       Date:  1972-06       Impact factor: 7.640

View more
  22 in total

1.  Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene.

Authors:  G Brunner; J Pohl; L J Erkell; A Radler-Pohl; V Schirrmacher
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

2.  Generation of altered transcripts by retroviral insertion within the c-myb gene in two murine monocytic leukemias.

Authors:  T J Gonda; S Cory; P Sobieszczuk; D Holtzman; J M Adams
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

Review 3.  Cancer genes generated by rare chromosomal rearrangements rather than activation of oncogenes.

Authors:  P H Duesberg
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

4.  ras transfection and expression does not induce progression from tumorigenicity to metastatic ability in mouse LTA cells.

Authors:  A B Tuck; S M Wilson; A F Chambers
Journal:  Clin Exp Metastasis       Date:  1990 Sep-Oct       Impact factor: 5.150

5.  Oncogene activation in human benign tumors of the skin (keratoacanthomas): is HRAS involved in differentiation as well as proliferation?

Authors:  M Corominas; H Kamino; J Leon; A Pellicer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

Review 6.  Cancer genes: rare recombinants instead of activated oncogenes (a review).

Authors:  P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell.

Authors:  R J Muschel; J E Williams; D R Lowy; L A Liotta
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

8.  Harvey ras genes transform without mutant codons, apparently activated by truncation of a 5' exon (exon -1).

Authors:  K Cichutek; P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

9.  Oncogene expression in related cancer lines differing in metastatic capacity.

Authors:  J Pohl; A Radler-Pohl; R Heicappell; V Schirrmacher
Journal:  Clin Exp Metastasis       Date:  1988 May-Jun       Impact factor: 5.150

10.  Molecular cloning and characterization of an activated human c-raf-1 gene.

Authors:  M Fukui; T Yamamoto; S Kawai; F Mitsunobu; K Toyoshima
Journal:  Mol Cell Biol       Date:  1987-05       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.